Generic drug makers are applauding the latest change to the health care bill — eliminating the ban on patent settlements.

The measure, which was backed by the Federal Trade Commission, would in most cases have barred so-called “pay for delay” settlements of patent cases brought by generic companies against brand-name drug makers. In such cases, the brand-name maker pays the generic company to delay the market entry of a lower-cost generic drug alternative.